As of the latest Form 4 filed May 1, 2026.
What Revelation Biosciences Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Newest filing first — the 12 most recent filings for REVB.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-05-01 | 2026-04-30 | Rolke James Chief Executive Officer | FTax | −10.1K | $1.13 | $11.4K | No | Form 4 ↗ |
| 2026-05-01 | 2026-04-30 | Zygmont Chester Stanley III Chief Financial Officer | FTax | −13.3K | $1.10 | $14.6K | No | Form 4 ↗ |
| 2026-02-05 | 2026-02-04 | Zygmont Chester Stanley III Chief Financial Officer | FTax | −13.1K | $1.65 | $21.6K | No | Form 4 ↗ |
| 2026-02-05 | 2026-02-03 | ROPER JESS Director | FTax | −1.59K | $1.85 | $2.94K | No | Form 4 ↗ |
| 2026-02-05 | 2026-02-03 | Chawla Lakhmir S Director | FTax | −2.26K | $1.85 | $4.18K | No | Form 4 ↗ |
| 2026-02-05 | 2026-02-03 | CARVER JENNIFER Director | FTax | −1.66K | $1.87 | $3.11K | No | Form 4 ↗ |
| 2026-02-05 | 2026-02-03 | Rolke James Chief Executive Officer | FTax | −8.52K | $1.86 | $15.8K | No | Form 4 ↗ |
| 2026-01-12 | 2026-01-08 | Rolke James Chief Executive Officer | AAward | +533K | $0.90 | $480K | No | Form 4 ↗ |
| 2026-01-12 | 2026-01-08 | Zygmont Chester Stanley III Chief Financial Officer | AAward | +78.1K | $0.90 | $70.3K | No | Form 4 ↗ |
| 2026-01-12 | 2026-01-08 | CARVER JENNIFER Director | AAward | +42.0K | $0.90 | $37.8K | No | Form 4 ↗ |
| 2026-01-12 | 2026-01-08 | ROPER JESS Director | AAward | +42.0K | $0.90 | $37.8K | No | Form 4 ↗ |
| 2026-01-12 | 2026-01-08 | Chawla Lakhmir S Director | AAward | +42.0K | $0.90 | $37.8K | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also REVB’s full analysis or the market-wide insider trading feed. The tabs above jump to REVB’s other SEC data.
Source: SEC Form 4 filings for REVB, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.